Amgen Inc. (AMGN) Holdings Lifted by Financial Advisory Service Inc.
Financial Advisory Service Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,974 shares of the medical research company’s stock after purchasing an additional 5 shares during the period. Financial Advisory Service Inc.’s holdings in Amgen were worth $340,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares in the last quarter. Capital Advisors Ltd. LLC raised its position in shares of Amgen by 0.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after acquiring an additional 7 shares in the last quarter. Investment Partners Ltd. OH ADV raised its position in shares of Amgen by 0.5% in the 2nd quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after acquiring an additional 11 shares in the last quarter. Conservest Capital Advisors Inc. raised its position in shares of Amgen by 0.4% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after acquiring an additional 13 shares in the last quarter. Finally, Arvest Bank Trust Division raised its position in shares of Amgen by 0.9% in the 2nd quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock worth $260,000 after acquiring an additional 13 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Amgen Inc. (AMGN) Holdings Lifted by Financial Advisory Service Inc.” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/amgen-inc-amgn-holdings-lifted-by-financial-advisory-service-inc/1637710.html.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.19% of the stock is owned by insiders.
Several research analysts have recently issued reports on AMGN shares. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Credit Suisse Group set a $177.00 target price on Amgen and gave the stock a “hold” rating in a research report on Friday, July 14th. Bank of America Corporation increased their target price on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $174.00 target price (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $189.99.
Amgen Inc. (AMGN) opened at 186.19 on Wednesday. The stock has a market capitalization of $135.86 billion, a P/E ratio of 16.96 and a beta of 1.36. The stock has a 50 day moving average price of $183.93 and a 200-day moving average price of $170.98. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.84 earnings per share. Equities research analysts expect that Amgen Inc. will post $12.58 EPS for the current year.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.